Deals in Depth: May 2009
Executive Summary
Top Tier Biotechs, as opposed to Big Pharma, featured as the prominent dealmakers with Celgene standing out thanks to its $540 million license to GlobeImmune's cancer programs. In M&As generics grabbed the attention of Novartis, which paid $1.2bn for Ebewe Pharma; meanwhile Covidien's $470 million takeover of Vnus expands its presence in the vascular market. The $1.2bn in biopharma financing was way up versus last month, but device fund-raising didn't fare as well, dropping 61%.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.